Company attributes
Other attributes
ExVivo Labs is building a platform to detect allergies through the skin, without the need for blood. ExVivo's patch extracts a sample of interstitial skin fluid and analyzes it for the presence of the allergy biomarker, also known as IgE. This is the same biomarker that's found in blood, and is the basis for several blood tests currently on the market.
On August 22, 2016 ExVivo Labs announced raising an undisclosed amount of seed funding from Y Combinator, Tencent Holdings, Pegasus Tech Ventures, OS Fund, Fifty Years, and 1517 Fund.
On September 15, 2016 ExVivo Labs announced raising a second undisclosed amount of seed funding from Y Combinator, Tencent Holdings, OS Fund, Fifty Years, and 1517 Fund.
On December 1, 2018 ExVivo Labs announced raising an undisclosed amount of venture funding from undisclosed investors.
